Francesca Negri

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 340 citations

Second-line Treatment, Hepatology, Medicine +10

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis

Roberta Castriconi, Alessandra Dondero, Raffaella Augugliaro et al. · Proceedings of the National Academy of Sciences · 2004 · 292 citations · Full text

Immunology, Immunoediting, Cell Death +18

Microsatellite instability in colorectal cancer.

Gian Luigi de’Angelis, Lorena Bottarelli, Nicola de’Angelis et al. · PubMed · 2018 · 172 citations · Full text

Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer

Francesca Negri, A. Wotherspoon, David Cunningham et al. · Annals of Oncology · 2005 · 160 citations

Gastrointestinal Oncology, Reduced Fluorouracil Responsiveness, Medicine +8

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Cecilia Bozzetti, Francesca Negri, Costanza Annamaria Lagrasta et al. · British Journal of Cancer · 2011 · 150 citations · Full text